… as well as the inspection burden, associated with the CAR-T process. The initial findings were presented at the 51st … departments. It is hoped that this will encourage CAR-T manufacturing companies to engage more closely with … Operational Burden and Fragmented Implementation in CAR T-cell Therapy: Insights from a Multinational Survey by …

… My presentation was about the standards in IECs, including CAR-T cells but also NK and dendritic cells. I tried to summarize … of my center and others in establishing a clinical CAR-T program. During the Q&A time, attendees mostly agreed …

… Patient in Focus: Delving into CAR-T cell therapy accessibility challenges This session at the 7th European CAR T-cell Meeting, promoted by the Patient Advocacy … Summary of the 7th European CAR T-Cell Meeting …

… Ram (Israel) for his abstract entitled: DAY+7 ANTI CD19-CAR-T BLOOD CONCENTRATIONS IDENTIFY ULTRA-HIGH-RISK GROUP FOR … Olga Molostova (Russian Federation) - OS13-01 CD19 CAR-T THERAPY IN CHILDREN WITH RELAPSED AND REFRACTORY B-CELL …

… its long-awaited Practice Recommendations for HCT and CAR-T Therapy . This ninth special report provides updated … such as the GoCART Coalition continue to spearhead CAR-T and immune effector cell therapy research. In 2025, the …

… CAR-T in elderly patients …

… greetings. A medical lecture on the future of CAR-T cell therapy introduced the first scientific session where … presented about advanced nursing practices caring for CAR-T patients. The role of research nurses in paediatric …

… trial at Kings College Hospital in London and received a CAR-T therapy. Matthew is telling his personal experience about … I dismissed them all other than the groundbreaking CAR-T therapy I had read so much about in the news. This was … Patient experience of CAR T-cell therapy …

… shared their experience in the field of transplant and CAR-T complications in the form of interactive case-based … cell-associated neurotoxicity syndrome (ICANS) after CAR-T therapy. The meeting program was enriched by discussion …

… therapy choice and then all the way to 4 th line including CAR-T, bispecifics and allogeneic stem cell transplantation. … inferior OS. The second line landscape is now dominated by CAR-T cell therapy according to the ZUMA-7 and TRANSFORM …